Royalty Pharma (RPRX) Earnings Date & Reports

Royalty Pharma's Q1 2026 (ended March 31, 2026) financials showed significant outperformance. Portfolio Receipts, the company's primary cash measure, hit $925 million, a 10% increase from $839 million in Q1 2025, exceeding analyst revenue consensus around $742 million–$891 million. Royalty Receipts, 96% of the total, surged 13% to $887 million, fueled by growth in Tremfya (+ contribution), Voranigo, and Evrysdi, offsetting Promacta declines due to U.S. generics.

Diluted earnings per share (EPS) came in at $0.67, up from $0.55 last year, beating lowered Wall Street expectations of $1.18–$1.22 (analyst focus often on adjusted metrics like Portfolio Cash Flow per share). Revenues totaled $631 million (up 11%), with net income attributable to common shareholders at $295 million. Adjusted EBITDA rose 21% to $889 million, and net cash from operations climbed 20% to $718 million.

A $69 million non-cash impairment on Tazverik royalty (due to withdrawal) was noted, but offset by operational strength. Guidance was raised: full-year Portfolio Receipts now $3.325–$3.450 billion (prior $3.275–$3.425 billion), with operating costs at 5.5%–6.5% of receipts.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (market cap), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across diverse portfolios. Explore the AI Screener today to enhance your stock analysis workflow.

Market Reaction and Investor Sentiment

Following the May 6, 2026 pre-market release, RPRX shares gained over 1% to around $51, signaling approval of the results and guidance raise. Sentiment turned bullish on Royalty Pharma's capital deployment ($528 million in Q1, including J&J and Teva R&D deals) and pipeline catalysts like daraxonrasib Phase 3 success. While EPS beat GAAP and adjusted expectations, revenue strength in Portfolio Receipts drove optimism, though some noted Tazverik impairment. Pre-earnings implied volatility highlighted risks from biosimilars, but results eased concerns.

Forward Outlook and Key Factors to Monitor

Royalty Pharma's raised 2026 guidance points to steady growth, with Portfolio Receipts projected at $3.325–$3.450 billion, reflecting 4%–8% Royalty Receipts expansion despite Promacta exclusivity loss and potential Tysabri biosimilar entry. Q2 guidance is $740–$760 million, accounting for tiered royalty resets.

Investors should track pipeline milestones: FDA filings for daraxonrasib (pancreatic cancer, NSCLC), litifilimab (lupus), and approvals like Avlayah (Hunter syndrome). Peak royalties could exceed $400 million for frexalimab and $180–$340 million for daraxonrasib. R&D co-funding expansion (e.g., up to $500 million each with J&J's JNJ-4804 and Teva's TEV-'408) diversifies revenue.

Balance sheet strength persists with $586 million cash, $9.2 billion debt (leverage 2.9x Adjusted EBITDA), and $4 billion liquidity. Dividend hikes (to $0.235/share) and $50 million buybacks continue. Watch cost trends, IRA effects on Medicare pricing, and new deal flow for compounding returns.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations